Fortune MNC 500 India 2026 edition
Rank#147- Total income
- ₹4,890 Cr
- Profit
- ₹1,070 Cr
Last year #149
Pfizer Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Active Listed - NSE: PFIZER · BSE: 500680 Public Limited Company pharma Fortune MNC 500 · #147 BSE 500
Market Cap
₹17,644 Cr
PFIZER · NSE
Share Price
₹3,856.00
-0.02% today
Revenue
₹2,520 Cr
FY 2025-26 · +10.5% YoY
EBITDA
₹855 Cr
Margin 33.9%
Net Profit
₹759 Cr
FY 2025-26 · +37.5% YoY
P/E (TTM)
21.5x
P/B 3.7x
ROE
17.2%
ROCE 22.6%
Debt / Equity
0.02
Interest cover 1.2x
About Pfizer Limited
Data last updated:
Pfizer Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 November 1950 and has been in existence for over 76 years.
Pfizer is ranked #147 on the Fortune MNC 500 India (2026). It is part of the BSE 500 index.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24231MH1950PLC008311. Its GSTIN is 27AAACP3334M1ZB (Maharashtra). The company holds 30 GST registrations, of which 21 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 500680 and NSE: PFIZER.
The company has an authorised share capital of ₹63 Cr and a paid-up capital of ₹45.75 Cr. It is led by directors including Meenakshi Nevatia (Managing Director) and Amit Agarwal (Whole-Time Director).
Its last annual general meeting (AGM) was held on 21 July 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at The Capital 1802 / 1901 Plot No. C – 70 G Block Bandra Kurla Complex Bandra (East), Mumbai, Maharashtra, India – 400051.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹2,519.65 Cr, a growth of 10.4% compared to the previous year. For the same year it recorded a net profit of ₹758.68 Cr (net margin 30.1%) and EBITDA of ₹855.02 Cr (EBITDA margin 33.9%). The net worth stands at ₹4,202.9 Cr (down 0.3% YoY). Total assets are valued at ₹4,328.55 Cr (down 1.2% YoY).
The company has about 1,727 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Pfizer. Court records list 1,220 cases involving the company, including 1,000 filed by the company and 221 filed against it; 286 cases are pending. The company has 7 deals on record (4 market trades, 3 acquisitions); the latest was in August 2026. Its 5 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 1 smaller; the largest is Shreya Life Sciences Private Limited with revenue of ₹2,946.23 Cr. The company has 12 MSME Form 1 returns on record between 2019 and 2024, listing 461 overdue payments to 110 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website pfizerindia.com.
Company details
CIN L24231MH1950PLC008311
Registration Number 008311
Incorporation Date 21 November 1950
ROC Mumbai
Listing Status Listed - Listed on NSE (PFIZER); Listed on BSE (500680)
Company Status Active
Date of Last AGM 21 July 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Meenakshi Nevatia Managing Director Amit Agarwal Whole-Time Director Pazhania Pillai Rengan Whole-Time Director Recognitions & Rankings of Pfizer
Stock market indices
BSE 500
Contact details
Pfizer Limited's registered office is in Mumbai, Maharashtra. Its website is pfizerindia.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressThe Capital 1802 / 1901 Plot No. C – 70 G Block Bandra Kurla Complex Bandra (East), Mumbai, Maharashtra, India – 400051
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Pfizer Limited, buy the company report.
Comprehensive company report
Pfizer Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Pfizer operates one associated brand: Pfizer. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical products for treating multiple diseases are provided. | pfizer.com |
Business activity
The main business activity of Pfizer is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Pfizer Limited, buy the company report.
Financials of Pfizer Limited
FY 2025-26 filings availablePfizer Limited reported revenue of ₹2,519.65 Cr (up 10.4% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹2,520 Cr
+10.4% YoY
EBITDA
₹855 Cr
+15.5% YoY
Profit After Tax
₹759 Cr
+37.5% YoY
Net Worth
₹4,203 Cr
-0.3% YoY
Total Assets
₹4,329 Cr
-1.2% YoY
Total Debt
₹70.23 Cr
-35.2% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2,520 | 2,281 | 2,193 | 2,425 | 2,611 | 2,239 | 2,152 |
| Revenue growth | +10.5% | +4.0% | -9.6% | -7.1% | +16.6% | +4.0% | - |
| EBITDA | 855 | 740 | 635 | 809 | 836 | 712 | 573 |
| EBITDA margin | +33.9% | +32.5% | +29.0% | +33.4% | +32.0% | +31.8% | +26.6% |
| Profit before tax | 976 | 1,016 | 746 | 824 | 773 | 669 | 642 |
| Net profit | 759 | 552 | 548 | 601 | 611 | 498 | 510 |
| Net profit margin | +30.1% | +24.2% | +25.0% | +24.8% | +23.4% | +22.2% | +23.7% |
| EPS (₹) | 157.91 | 167.78 | 120.51 | 136.38 | 133.89 | 108.77 | 111.29 |
| Balance sheet | |||||||
| Total assets | 4,329 | 4,382 | 3,722 | 3,385 | 3,087 | 2,555 | 3,535 |
| Net worth | 4,203 | 4,217 | 3,596 | 3,207 | 2,864 | 2,393 | 3,395 |
| Total debt | 70.23 | 108 | 40.19 | 41.15 | 39.25 | 63.23 | 2.50 |
| Cash & bank | 3,111 | 2,801 | 2,047 | 1,860 | 1,643 | 1,115 | 2,220 |
| Net working capital | 3,210 | 2,984 | 2,231 | 1,909 | 1,583 | 1,197 | 2,177 |
| Cash flow | |||||||
| Cash from operations | 968 | 660 | 257 | 356 | 667 | 427 | 323 |
| Cash from investing | (562) | (71.34) | 53.70 | (36.05) | (575) | (469) | 1,530 |
| Cash from financing | (798) | (205) | (235) | (346) | (181) | (1,571) | (164) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 727 | 653 | 629 | 645 | 642 | 603 | 592 | 538 |
| Revenue growth (YoY) | +13.2% | +8.3% | +6.3% | +19.9% | +9.1% | +7.1% | - | - |
| Other income | 179 | 44.84 | 49.76 | 38.21 | 41.85 | 67.17 | 217 | 42.76 |
| Total expenses | 466 | 406 | 393 | 475 | 412 | 393 | 364 | 392 |
| EBITDA | 261 | 248 | 236 | 170 | 230 | 210 | 228 | 146 |
| EBITDA margin | +35.9% | +37.9% | +37.5% | +26.4% | +35.8% | +34.8% | +38.4% | +27.1% |
| Depreciation | 14.41 | 14.26 | 14.78 | 14.26 | 14.28 | 14.41 | 16.40 | 14.80 |
| Interest | 3.35 | 1.46 | 2.11 | 1.99 | 2.13 | 3.25 | 2.69 | 1.51 |
| Profit before tax | 423 | 277 | 269 | 192 | 255 | 260 | 426 | 172 |
| Tax | 110 | 72.21 | 69.00 | 50.11 | 66.35 | 67.78 | 94.86 | 44.84 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 07 Nov 2026
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 727 | 653 | 629 | 645 | 642 | 603 | 592 | 538 |
| Revenue growth (YoY) | +13.2% | +8.3% | +6.3% | +19.9% | +9.1% | +7.1% | - | - |
| Other income | 179 | 44.84 | 49.76 | 38.21 | 41.85 | 67.17 | 217 | 42.76 |
| Total expenses | 466 | 406 | 393 | 475 | 412 | 393 | 364 | 392 |
| EBITDA | 261 | 248 | 236 | 170 | 230 | 210 | 228 | 146 |
| EBITDA margin | +35.9% | +37.9% | +37.5% | +26.4% | +35.8% | +34.8% | +38.4% | +27.1% |
| Depreciation | 14.41 | 14.26 | 14.78 | 14.26 | 14.28 | 14.41 | 16.40 | 14.80 |
| Interest | 3.35 | 1.46 | 2.11 | 1.99 | 2.13 | 3.25 | 2.69 | 1.51 |
| Profit before tax | 423 | 277 | 269 | 192 | 255 | 260 | 426 | 172 |
| Tax | 110 | 72.21 | 69.00 | 50.11 | 66.35 | 67.78 | 94.86 | 44.84 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,520 | 2,281 | 2,193 | 2,425 | 2,611 | 2,239 | 2,152 |
| Revenue growth | +10.5% | +4.0% | -9.6% | -7.1% | +16.6% | +4.0% | - |
| Other income | 188 | 345 | 188 | 134 | 62.65 | 81.12 | 184 |
| Total expenses | 1,665 | 1,541 | 1,558 | 1,616 | 1,775 | 1,526 | 1,579 |
| Employee cost | 368 | 371 | 348 | 332 | 404 | 361 | 365 |
| EBITDA | 855 | 740 | 635 | 809 | 836 | 712 | 573 |
| EBITDA margin | +33.9% | +32.5% | +29.0% | +33.4% | +32.0% | +31.8% | +26.6% |
| Depreciation | 57.73 | 60.79 | 62.28 | 106 | 115 | 109 | 103 |
| Interest | 9.57 | 8.50 | 15.43 | 13.48 | 10.70 | 15.39 | 11.01 |
| Profit before tax | 976 | 1,016 | 746 | 824 | 773 | 669 | 642 |
| Tax | 253 | 248 | 195 | 200 | 160 | 171 | 133 |
| Net profit | 759 | 552 | 548 | 601 | 611 | 498 | 510 |
| Net profit margin | +30.1% | +24.2% | +25.0% | +24.8% | +23.4% | +22.2% | +23.7% |
| EPS (₹) | 157.91 | 167.78 | 120.51 | 136.38 | 133.89 | 108.77 | 111.29 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 45.75 | 45.75 | 45.75 | 45.75 | 45.75 | 45.75 | 45.75 |
| Reserves & surplus | 4,157 | 4,172 | 3,550 | 3,162 | 2,819 | 2,347 | 3,350 |
| Shareholders' funds (net worth) | 4,203 | 4,217 | 3,596 | 3,207 | 2,864 | 2,393 | 3,395 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 70.23 | 108 | 40.19 | 41.15 | 39.25 | 63.23 | 2.50 |
| Total debt | 70.23 | 108 | 40.19 | 41.15 | 39.25 | 63.23 | 2.50 |
| Total liabilities | 4,329 | 4,382 | 3,722 | 3,385 | 3,087 | 2,555 | 3,535 |
| Assets | |||||||
| Gross block | 1,418 | 1,418 | 1,356 | 1,352 | 1,383 | 1,316 | 1,315 |
| Net block | 678 | 724 | 713 | 749 | 869 | 894 | 973 |
| Capital work in progress | 20.00 | 7.64 | 0.40 | 7.93 | 1.15 | 2.76 | 0.76 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 473 | 476 | 434 | 418 | 449 | 435 | 431 |
| Sundry debtors | 182 | 193 | 188 | 152 | 143 | 109 | 172 |
| Cash & bank balances | 3,111 | 2,801 | 2,047 | 1,860 | 1,643 | 1,115 | 2,220 |
| Loans & advances | 38.00 | 42.86 | 69.80 | 96.14 | 162 | 250 | 226 |
| Total current assets | 3,803 | 3,513 | 2,738 | 2,525 | 2,396 | 1,908 | 3,048 |
| Total current liabilities | 593 | 529 | 506 | 616 | 814 | 711 | 871 |
| Net working capital | 3,210 | 2,984 | 2,231 | 1,909 | 1,583 | 1,197 | 2,177 |
| Total assets | 4,329 | 4,382 | 3,722 | 3,385 | 3,087 | 2,555 | 3,535 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 495 | 112 | 36.60 | 62.76 | 151 | 1,764 | 73.81 |
| Net cash from operating activities | 968 | 660 | 257 | 356 | 667 | 427 | 323 |
| Net cash from investing activities | (562) | (71.34) | 53.70 | (36.05) | (575) | (469) | 1,530 |
| Net cash from financing activities | (798) | (205) | (235) | (346) | (181) | (1,571) | (164) |
| Net change in cash | (392) | 383 | 75.40 | (26.16) | (88.45) | (1,613) | 1,690 |
| Closing cash | 3,111 | 2,801 | 2,047 | 1,860 | 1,643 | 1,115 | 2,220 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +10.5% | +4.0% | -9.6% | -7.1% | +16.6% | +4.0% | - |
| EBITDA growth | +15.5% | +16.5% | -21.5% | -3.2% | +17.3% | +24.4% | - |
| PBT growth | -4.0% | +36.2% | -9.5% | +6.6% | +15.6% | +4.1% | -2.6% |
| Net income growth | +37.5% | +0.8% | -8.9% | -1.7% | +22.9% | -2.4% | - |
| Revenue CAGR (3Y) | +1.3% | -4.4% | -0.7% | +4.1% | +7.9% | +4.4% | +3.1% |
| EBITDA CAGR (3Y) | +1.9% | -4.0% | -3.8% | +12.2% | +13.9% | +12.5% | +17.8% |
| Profitability & leverage | |||||||
| Net income margin | +28.7% | +33.7% | +25.1% | +25.7% | +23.5% | +22.2% | +23.7% |
| Return on capital employed | +22.6% | +21.1% | +21.4% | +25.9% | +27.8% | +22.5% | +19.9% |
| Return on net worth | +17.2% | +16.4% | +16.2% | +20.6% | +23.3% | +17.2% | +15.9% |
| Debt / equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 |
| Long-term debt / equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 1.20 | 1.25 | 2.69 | 1.92 | 1.48 | 2.55 | 2.35 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.78 | 1.64 | 1.62 | 1.77 | 1.93 | 1.70 | 1.75 |
| Inventory turnover | 5.31 | 5.02 | 5.15 | 5.60 | 5.91 | 5.17 | 5.27 |
| Debtors turnover | 13.44 | 11.99 | 12.93 | 16.48 | 20.78 | 15.94 | 12.52 |
| EPS (₹) | 157.91 | 167.78 | 120.51 | 136.38 | 133.89 | 108.77 | 111.29 |
| Dividend per share (₹) | 75.00 | 165.00 | 35.00 | 40.00 | 35.00 | 35.00 | 330.00 |
| Book value per share (₹) | 918.67 | 921.84 | 785.91 | 701.05 | 626.10 | 523.07 | 742.18 |
To see the full year-wise statements and ratios of Pfizer Limited, buy the company report.
Board of directors of Pfizer Limited
Pfizer has 7 current directors and 18 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Meena Ganesh | Director | 08 Mar 2019 | 7 Years 7 Months | Current |
| Pradip Panalal Shah Also directs: Basf India Limited, Bajaj Holdings & Investment Limited., Bajaj Auto Limited. and 5 more | Director | 07 Dec 1999 | 26 Years 11 Months | Current |
| Lakshmanan Krishna Kumar Also directs: Infiniti Retail Limited, Tata Consulting Engineers Limited | Director | 29 Jul 2024 | 2 Years 3 Months | Current |
| Sonia Singh | Director | 29 Jul 2024 | 2 Years 3 Months | Current |
| Amit Agarwal | Whole-Time Director | 30 Mar 2024 | 2 Years 7 Months | Current |
| Pazhania Pillai Rengan | Whole-Time Director | 06 Jan 2024 | 2 Years 10 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer comparison
Pfizer Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Shreya Life Sciences Private Limited | ₹2,946.23 Cr (FY 2025) | 284.0% | Mumbai, Maharashtra, India | |||
| Amneal Pharmaceuticals Private Limited | ₹2,944.87 Cr (FY 2025) | 6.0% | Ahmedabad, Gujarat, India | |||
| Sandoz Private Limited | ₹2,778.2 Cr (FY 2025) | -2.0% | Navi Mumbai, Maharashtra, India | |||
| Biological E. Limited | ₹2,708 Cr (FY 2024) | -30.0% | Telangana, India | |||
| Pfizer Limitedthis company | ₹2,519.65 Cr (FY 2026) | ₹758.68 Cr | 30.1% | 10.4% | 1,727 | Mumbai, Maharashtra, India |
| Merck Life Science Private Limited | ₹2,200.06 Cr (FY 2025) | 7.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Pfizer Limited, buy the company report.
Auditor
Pfizer Limited is audited by B S R & Co. LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| B S R & Co. LLP | FY 2023 | 101248W/W-100022 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 63.90%, foreign institutional investors hold 1.60%, domestic institutional investors hold 17.80% and retail and other public shareholders hold 16.70%.
Sep 2026
QUARTER
63.90% Promoters
17.80% DII (Domestic Institutional)
1.60% FII (Foreign Institutional)
16.70% Retail & Others
Promoter holding - history
Now 63.90% · Sep 2026High 63.90% · Dec 2025Low 63.90% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 63.90% | 63.90% | 63.90% | 63.90% |
| Public | 36.10% | 36.10% | 36.10% | 36.10% |
Deals & funding
Pfizer Limited has 7 deals on record (4 market trades, 3 acquisitions); the latest was in August 2026.
Total deals
7
Market trades
4
Acquisitions
3
Deals on record (5 of 7)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2026 | Market trade | ₹131.25 Cr | Buyer: Quant Mutual Fund |
| Apr 2026 | Market trade | ₹200.25 Cr | Buyer: Prudential Icici Mutual Fund A/C Discovery Fund Seller: Goldman Sachs Funds - Goldman Sachs India Equity Portfolio |
| May 2016 | Acquisition | ₹110.02 Cr | Buyer: Piramal Enterprises Ltd Seller: Pfizer Limited |
| Sep 2015 | Acquisition | ₹178.25 Cr | Buyer: Vidhi Research & Development LLP Seller: Pfizer Limited |
| Nov 2002 | Acquisition | ₹34.9 Cr | Buyer: Eac Trading Private Limited Seller: Pfizer Limited |
To see the full deal history of Pfizer Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Pfizer Limited has 1,220 court cases on record: 1,000 filed by Pfizer, 221 filed against it. 286 cases are pending and 934 are disposed.
Total cases
1,220
Filed by the company
1,000
Filed against the company
221
Pending
286
Disposed
934
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 906 | 101 | 210 |
| High courts | 294 | 106 | 75 |
| Supreme Court | 20 | 14 | 1 |
Cases on record (5 of 1,220)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court for State of Telangana | Court case (CCCA) | Filed by the company against M/S Rci Logistics Private Limited | Pending |
| High Court of Delhi | Appeal | Filed against the company by Rodec Pharmaceuticals Pvt Ltd | Disposed |
| District court, South, Delhi | Interim or miscellaneous application | Filed against the company by Rodec Pharmaceuticals Pvt. Ltd. | Disposed |
| District court, Chandigarh | Court case (SUCC) | Filed against the company | Pending |
| Bombay High Court | Interim or miscellaneous application | Filed against the company by PR Commissioner of Income Tax 6 Mumbai | Pending |
To see the full case history of Pfizer Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Pfizer Limited has 12 MSME Form 1 returns on record between 2019 and 2024, listing 461 overdue payments to 110 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 110)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Bitonic Technology Labs Private Limited | |||
| an individual supplier | |||
| Elegant Chemical Enterprises Pvt Ltd | |||
| Printania Offset Private Limited | |||
| Mudrak |
To see the full MSME payment records of Pfizer Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Pfizer Limited has a workforce of 1,727 employees on its EPFO records as of Mar 21, 2024, across 3 active EPFO establishments.
Employee count
1,727
Active EPFO establishments
3
Employee growth
-6.65%
GST
Pfizer has 30 GST registrations: 21 active and 9 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
30
Active
21
Cancelled / inactive
9
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACP3334M1ZB | Maharashtra | Active | 01 Jul 2017 |
| 27AAACP3334M2ZA | Maharashtra | Active | 14 Jul 2017 |
| 03AAACP3334M1ZL | Punjab | Active | 01 Jul 2017 |
| 07AAACP3334M1ZD | Delhi | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Pfizer Limited, buy the company report.
Recent activity
Pfizer Limited has 42 board changes on record since 1965: 25 appointments and 17 cessations. The latest: Sunil Siddharth Lalbhai ceased to be Director on 13 Feb 2025.
Filing
Pfizer Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Pfizer Limited last Annual general meeting of members was held on 21 Jul 2025 as per latest MCA records.
Ceased
Sunil Siddharth Lalbhai ceased to be Director.
Ceased
Uday Chander Khanna ceased to be Director.
Appointed
Lakshmanan Krishna Kumar was appointed as Director.
Appointed
Sonia Singh was appointed as Director.
Appointed
Amit Agarwal was appointed as Whole-Time Director.
Appointed
Pazhania Pillai Rengan was appointed as Whole-Time Director.
Ceased
Milind Anil Patil ceased to be CFO.
Ceased
Samir Salauddin Kazi ceased to be Whole-Time Director.
Appointed
Meenakshi Nevatia was appointed as Managing Director.
Ceased
Sridhar Subramaniam ceased to be Managing Director.
33 earlier events are in the company report.
News
PFIZER: Q2 SL NET PROFIT 3.13B RUPEES VS 1.89B (YOY)
PFIZER: Q2 EBITDA 2.6B RUPEES VS 2.3B (YOY); Q2 EBITDA MARGIN 35.94% VS 35.8% (YOY)
PFIZER: Q2 REVENUE 7.3B RUPEES VS 6.42B (YOY)
Frequently asked questions
Pfizer is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 21 November 1950 (76+ years old) and is registered under CIN L24231MH1950PLC008311. Listed on BSE: 500680 and NSE: PFIZER.
Pfizer reported revenue of ₹2,519.65 Cr for FY 2025-26 (up 10.4% YoY) based on standalone financials.
Pfizer has 7 current directors:
- Meenakshi Nevatia - Managing Director
- Amit Agarwal - Whole-Time Director
- Pazhania Pillai Rengan - Whole-Time Director
- Meena Ganesh - Director
- Pradip Panalal Shah - Director
- Lakshmanan Krishna Kumar - Director
- Sonia Singh - Director
The latest financial statements of Pfizer on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 21 July 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Pfizer is 27AAACP3334M1ZB, registered in Maharashtra. The company has 30 GST registrations in all, of which 21 are active and 9 are cancelled or inactive. Other active GSTINs include 27AAACP3334M2ZA (Maharashtra), 03AAACP3334M1ZL (Punjab), 07AAACP3334M1ZD (Delhi).
The CIN (Corporate Identification Number) of Pfizer is L24231MH1950PLC008311. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Pfizer is a listed company as per MCA records. Its shares are listed on both BSE (code: 500680) and NSE (symbol: PFIZER).
Pfizer has 1,220 court cases on record: 1,000 filed by the company and 221 filed against it. 286 are pending. Most are in the district courts.
Pfizer was incorporated on 21 November 1950, making it 76+ years old. It is registered with the Registrar of Companies, Mumbai.
Pfizer has 7 deals on record (4 market trades, 3 acquisitions); the latest was in August 2026.
The peers of Pfizer by revenue are Shreya Life Sciences Private Limited, Amneal Pharmaceuticals Private Limited, Sandoz Private Limited, Biological E. Limited, Merck Life Science Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Sunil Siddharth Lalbhai ceased to be Director on 13 Feb 2025. Uday Chander Khanna ceased to be Director on 09 Nov 2024. Lakshmanan Krishna Kumar was appointed as Director on 29 Jul 2024. Pfizer has 42 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages